Conference Coverage

Thirty-second atrial fib threshold may drive overdiagnosis


 

REPORTING FROM HEART RHYTHM 2018


He and his associates used data collected by Medtronic from 1,040 patients enrolled in a company registry during 2005-2016 with an implanted dual-chamber pacemaker able to detect atrial arrhythmias. The researchers focused on the 615 patients who had AF detected during at least 30 days of monitoring. These 615 patients averaged 72 years of age, 54% were men, and 599 had at least one AF episode of at least 30 seconds duration. Each patient had an average 3.7-year accumulated archive of atrial rhythm data.

The analysis showed a close association between the longest AF episode detected and overall AF burden. Among patients with a longest episode of 30-119 seconds, the median burden was 0.1%. Among patients with a maximum duration of anywhere from 30 seconds to 3.7 hours, the median burden was 0.2%. But among people with a longest episode of 3.8 hours to 5.4 hours, the median burden was 1.2%. In those with a longest episode of at least 24 hours, the median burden was 25%. Finally, in those who had a longest AF episode that lasted at least 3.8 hours, the median AF burden was 9.5%.

Dr. Steinberg acknowledged that a very important additional step needed in this analysis is examining the correlations among AF burden, longest AF episode, and stroke incidence, something he and his associates are now doing. He expressed hope that these data will spur the cardiac electrophysiology community to rethink its AF definition.

The study was funded by Medtronic. Dr. Steinberg has been a consultant and/or has received research funding from Medtronic, AliveCor, Allergen, Atricure, Biosense Webster, G Medical, and National Cardiac. Several of his coauthors were Medtronic employees.

SOURCE: Steinberg J et al. Heart Rhythm Society scientific sessions, B-P001-062.

Pages

Recommended Reading

Takotsubo cardiomyopathy incidence, mortality on the rise
MDedge Cardiology
Permanent His-bundle pacing superior to RV pacing
MDedge Cardiology
MDedge Daily News: Time to let more pregnant women into drug trials?
MDedge Cardiology
Apixaban prevails in study of 163,000 DOAC users
MDedge Cardiology
VIDEO: Screening ECG patch boosts AF diagnoses ninefold
MDedge Cardiology
MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Cardiology
Women’s representation in CV drug trials still lagging
MDedge Cardiology
First reversal agent for apixaban and rivaroxaban gets fast-track approval
MDedge Cardiology
Adding vasopressin in distributive shock may cut AF risk
MDedge Cardiology
Novel targeted cancer drugs cause fewer arrhythmias
MDedge Cardiology